Post-treatment renal function deterioration following radiation therapy: implications for SABR in primary renal cell cancer - Takeaways - MDSpire

Post-treatment renal function deterioration following radiation therapy: implications for SABR in primary renal cell cancer

  • By

  • Marthe Sophie Kilian

  • Laura Anna Fischer

  • Jona Bensberg

  • Lisa-Antonia von Diest

  • Carla Marie Zwerenz

  • Mahalia Z. Anczykowski

  • Stephanie Bendrich

  • Manuel Guhlich

  • Martin Leu

  • Leif Hendrik Dröge

  • Tibor I. Kesztyüs

  • Annemarie Uhlig

  • Stefan Rieken

  • Rami A. El Shafie

  • June 23, 2026

  • 0 min

Share

  • 1

    Stereotactic ablative radiotherapy (SABR) shows promising local control and renal function outcomes similar to surgical interventions.

  • 2

    In a study of 232 patients, 46.98% experienced chronic kidney disease (CKD) progression post-radiation therapy.

  • 3

    Increased renal dose was identified as an independent predictor of renal function decline, with specific thresholds established.

  • 4

    Female gender was associated with a higher risk of renal function decline after radiation therapy.

  • 5

    The study highlights the need for further validation of nephron-sparing SABR strategies to minimize late kidney damage.

Original Source(s)

Related Content